Wolverine Asset Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

Wolverine Asset Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,141	Closed	–	–	2197
2021 Q3	$0	Buy	+2,141	New	+$901	﹤0.01%	2296
2021 Q1	–	Sell	-42,308	Closed	-$28K	–	2240
2020 Q4	$28K	Buy	42,308 +14,308	+51%	+$7.85K	﹤0.01%	1412
2020 Q3	$14K	Hold	28,000	–	–	﹤0.01%	1434
2020 Q2	$13K	Buy	28,000 +3,000	+12%	+$703	﹤0.01%	1403
2020 Q1	$2K	Buy	+25,000	New	+$3.74K	﹤0.01%	1401

Other funds holding RVPHW

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Wolverine Asset Management's RVPHW Position: Q4 2021 in Review

Wolverine Asset Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q4 2021, closing a stake of 2,141 shares.

Wolverine Asset Management first reported a position in RVPHW in Q1 2020 and held it in 5 quarters. The position peaked at $28K in Q4 2020. 6 funds tracked by Wall St. Rank hold RVPHW as of Q4 2021.

Wolverine Asset Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q4 2021 after selling out during the quarter.
Wolverine Asset Management sold 2,141 Reviva Pharmaceuticals Warrants shares in Q4 2021.
Wolverine Asset Management first reported a position in Reviva Pharmaceuticals Warrants in Q1 2020 and held it in 5 quarters.
Wolverine Asset Management's Reviva Pharmaceuticals Warrants position peaked at $28K in Q4 2020.
6 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q4 2021.

Based on Wolverine Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.